Biogen Idec Inc (BIIB): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec ( BIIB) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.6%. By the end of trading, Biogen Idec rose $3.48 (1.2%) to $297.48 on average volume. Throughout the day, 1,391,804 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,252,300 shares. The stock ranged in a price between $293.19-$298.98 after having opened the day at $293.60 as compared to the previous trading day's close of $294.00. Other companies within the Drugs industry that increased today were: Stemline Therapeutics ( STML), up 39.5%, ImmunoCellular Therapeutics ( IMUC), up 18.9%, Idenix Pharmaceuticals ( IDIX), up 17.1% and Bacterin International Holdings ( BONE), up 16.9%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $70.1 billion and is part of the health care sector. The company has a P/E ratio of 41.7, above the S&P 500 P/E ratio of 17.7. Shares are up 5.2% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Cormedix ( CRMD), down 10.9%, Galectin Therapeutics ( GALT), down 10.8%, Agios Pharmaceuticals ( AGIO), down 9.8% and Prosensa Holding N.V ( RNA), down 7.9% , were all laggards within the drugs industry with Incyte ( INCY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire